Malignant neoplasm of hepatic flexure
ICD-10 C18.3 is a billable code used to indicate a diagnosis of malignant neoplasm of hepatic flexure.
C18.3 refers to a malignant neoplasm located at the hepatic flexure of the colon, which is the bend between the ascending colon and the transverse colon. This area is significant in colorectal cancer (CRC) as it can be a site for tumor development due to various risk factors including age, family history, and lifestyle choices. Colorectal cancer is characterized by the uncontrolled growth of abnormal cells in the colon or rectum, often presenting with symptoms such as changes in bowel habits, rectal bleeding, and abdominal discomfort. Screening for colorectal cancer typically begins at age 45, with methods including colonoscopy, fecal occult blood tests, and imaging studies. Staging of the cancer is crucial for determining treatment options and prognosis, with the TNM system being the most widely used. Additionally, microsatellite instability (MSI) testing can provide insights into the tumor's genetic characteristics, influencing treatment decisions. Surgical approaches may include resection of the affected segment of the colon, often accompanied by chemotherapy or radiation therapy depending on the stage of the disease.
Detailed pathology reports, imaging studies, and treatment plans.
Diagnosis and treatment planning for colorectal cancer, follow-up care post-surgery.
Ensure accurate staging and documentation of treatment response.
Endoscopy reports, biopsy results, and screening recommendations.
Screening for colorectal cancer, management of polyps, and follow-up after diagnosis.
Document the rationale for screening and any findings during procedures.
Used for screening or diagnosis of colorectal cancer.
Indication for procedure, findings, and any biopsies taken.
Gastroenterologists should document findings thoroughly to support coding.
Microsatellite instability (MSI) is a condition of genetic hypermutability that can indicate a higher risk for certain types of colorectal cancer, particularly in patients with Lynch syndrome. Testing for MSI can help guide treatment decisions, including the use of immunotherapy.
